Cancer test kit

for NRAS mutationsplasmaurine

[Intended use] NRAS somatic mutations occur most frequently in melanoma (20%) and myeloid leukaemias. These mutations, activating their protein product, occur in codons 12, 13, and 61, with the codon 61 being by far the most frequent. This kit detects thirteen common mutations in exons 2 and 3 of the NRAS gene with a total frequency of 89.3% The kits can be used for 1) early screening and early diagnosis of cancer, 2) early monitoring of cancer relapse, and 3) selection of targeted therapy. [Detection principle] This kit uses pyrophosphorolysis activated polymerization (PAP ) technology to specifically amplify the mutant DNA but not wildtype DNA molecules. The amplified product is measured in real time fluorescence format. [Samples] Fresh and frozen tissues, paraffin-embedded tissues, plasma and urine. [Advantages] 1. High sensitivity: ability to detect a single copy of NRAS mutations. 2. High specificity: virtually no false positive amplifications even in the presence of heavy background of wildtype DNA. 3.Freeze-dried format: much earlier and user-friendly manipulation. 4. Non-invasive sampling: plasma and urine samples can be applied.